



Karyopharm Therapeutics
Investor Relations Department
85 Wells Ave, 2nd floor
Newton, MA 02459
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: KPTI

Last Trade:	9.22
Trade Time:	9:55 AM ET Dec 18, 2017
Change:	-0.02 (-0.216%)
Day Range	9.16 - 9.35
52-Week Range	7.48 - 14.63
Volume	14,520

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Corporate Profile

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmu... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Dec 10, 2017*
[Karyopharm Presents Positive Phase 1/2 Eltanexor Data at the American Society of Hematology 2017 Annual Meeting](#)
- Dec 10, 2017*
[Karyopharm Presents Positive Selinexor Data from the Phase 1b/2 STOMP Study at the American Society of Hematology 2017 Annual Meeting](#)
- Nov 13, 2017*
[Karyopharm Therapeutics to Present at the Jefferies 2017 London Healthcare Conference](#)
- Nov 3, 2017*
[Karyopharm Therapeutics to Participate in the Credit Suisse 26th Annual Healthcare Conference](#)
- Nov 2, 2017*
[Karyopharm Reports Third Quarter 2017 Financial Results and Highlights Recent Progress](#)

Financials [\[View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 16, 2017*
[Annual Report \(10-K\)](#)
- Apr 28, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 2, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 8, 2017*
[Quarterly Report \(10-Q\)](#)
- May 4, 2017*
[Quarterly Report \(10-Q\)](#)